{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:56:09Z","timestamp":1793328969982,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"swissHADRON foundation"},{"DOI":"10.13039\/501100011699","name":"Siemens Healthineers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess early tumor response with quantitated SPECT\/CT and to correlate it with clinical outcome in metastatic castration\u2013resistant prostate cancer (mCRPC) patients treated with <jats:sup>177<\/jats:sup>Lutetium-PSMA I&amp;T therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Single-center, observational study, part of the prospective Swiss national cancer registry study investigating the safety and efficacy of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA I&amp;T (EKNZ: 2021\u201301271) in mCRPC patients treated with at least two cycles of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA I&amp;T 6-weekly. After the first and second cycle quantitated SPECT\/CT (Symbia Intevo, Siemens) was acquired 48\u00a0h after injection (three fields of view from head to thigh, 5\u00a0s\/frame) and reconstructed using xQuant\u00ae (48i, 1\u00a0s, 10-mm Gauss). Image analysis: The PSMA-positive total tumor volumes (TTV) were semi-automatically delineated using a SUV threshold of 3 with MIMencore\u00ae (version 7.1.3, Medical Image Merge Software Inc.). Changes in TTV, highest tumor SUVmax, and total tumor SUVmean between cycles 1 and 2 were calculated and grouped into a) stable or decrease and b) increase. Serum PSA levels were assessed at each therapy cycle and at follow-up until progression or death. Changes in TTV, PSA, SUVmax, and SUVmean were correlated with PSA-progression-free survival (PSA-PFS) and the overall survival (OS) using the Kaplan\u2013Meier methodology (log-rank test).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 07\/2020 and 04\/2022, 111 patients were screened and 73 finally included in the data analysis. The median follow-up was 8.9\u00a0months (range 1.4\u201326.6\u00a0months). Stable or decreased TTV at cycle 2 was associated with longer OS (hazard ratio (HR) 0.28, 95% confidence interval (CI) 0.09\u20130.86, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Similar, stable, or decreased PSA was associated with longer OS (HR 0.21; CI 0.07\u20130.62, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and PSA-PFS (HR 0.34; 95% CI 0.16\u20130.72, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Combining TTV and PSA will result in an augmented prognostic value for OS (HR 0.09; CI 0.01\u20130.63; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and for PSA-PFS (HR 0.11; CI 0.02\u20130.68; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). A reduction of SUVmax or SUVmean was not prognostically relevant, neither for OS (<jats:italic>p<\/jats:italic> 0.88 and 0.7) nor for PSA-PFS (<jats:italic>p<\/jats:italic> 0.73 and 0.62, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Six weeks after initiating [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA I&amp;T, TTV and serum PSA appear to be good prognosticators for OS. Combined together, TTV\u2009+\u2009PSA change demonstrates augmented prognostic value and can better predict PSA-PFS. Larger studies using TTV change prospectively as an early-response biomarker are warranted for implementing management change towards a more personalized clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06536-2","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T07:03:31Z","timestamp":1701414211000},"page":"1185-1193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Early response monitoring during [177Lu]Lu-PSMA I&amp;T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0643-0036","authenticated-orcid":false,"given":"Moritz C.","family":"Neubauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume P.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Nitzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Forrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Rentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Chirindel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"all investigators on behalf of the SSNM Therapy Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"issue":"8","key":"6536_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, M\u00fcller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63(8):1199\u2013207. https:\/\/doi.org\/10.2967\/jnumed.121.262713.","journal-title":"J Nucl Med"},{"key":"6536_CR2","doi-asserted-by":"publisher","unstructured":"Fallah J, et al. FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;OF1\u2013OF7. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2875.","DOI":"10.1158\/1078-0432.CCR-22-2875"},{"issue":"12","key":"6536_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"6536_CR4","doi-asserted-by":"publisher","unstructured":"John N, et al. 177 Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression free survival for patients undergoing Lu PSMA I&T therapy. J Nucl Med. 2022;jnumed.122.264677. https:\/\/doi.org\/10.2967\/jnumed.122.264677.","DOI":"10.2967\/jnumed.122.264677"},{"key":"6536_CR5","doi-asserted-by":"publisher","unstructured":"Pathmanandavel S, et al. Evaluation of 177 Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177 Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2022;jnumed.122.264398. https:\/\/doi.org\/10.2967\/jnumed.122.264398.","DOI":"10.2967\/jnumed.122.264398"},{"key":"6536_CR6","doi-asserted-by":"publisher","unstructured":"A. Gafita et al. Novel framework for treatment response evaluation using PSMA-PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;jnumed.121.263072. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","DOI":"10.2967\/jnumed.121.263072"},{"issue":"12","key":"6536_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6536_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38(1):200\u201317. https:\/\/doi.org\/10.1148\/rg.2018170108.","journal-title":"Radiographics"},{"issue":"sup1","key":"6536_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/0284186X.2010.542174","volume":"50","author":"SF Shariat","year":"2011","unstructured":"Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50(sup1):61\u201375. https:\/\/doi.org\/10.3109\/0284186X.2010.542174.","journal-title":"Acta Oncol"},{"issue":"11","key":"6536_CR10","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1002\/cncr.11821","volume":"98","author":"AJ Birtle","year":"2003","unstructured":"Birtle AJ, Freeman A, Masters JRW, Payne HA, Harland SJ, Contributors to the BAUS Section of Oncology Cancer Registry. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng\/mL: the\u202f?PSA negative? patients. Cancer. 2003;98(11):2362\u20137. https:\/\/doi.org\/10.1002\/cncr.11821.","journal-title":"Cancer"},{"issue":"5","key":"6536_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1148\/rg.2020200058","volume":"40","author":"FG Barbosa","year":"2020","unstructured":"Barbosa FG, et al. Prostate-specific membrane antigen PET: therapy response assessment in metastatic prostate cancer. Radiographics. 2020;40(5):1412\u201330. https:\/\/doi.org\/10.1148\/rg.2020200058.","journal-title":"Radiographics"},{"issue":"8","key":"6536_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22(8):1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"},{"issue":"10276","key":"6536_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06536-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:07:11Z","timestamp":1708502831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06536-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6536"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06536-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Basel, Basel, Switzerland (EKNZ: 2021\u201301271).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Damian Wild received grants from Siemens Healthineers. All other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}